CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.47B, above the global median of $1.18B
- PositionOperating margin is 41.6%, higher than 95% of its Medical Devices peers (median 7.3%)
- Interpretations18 currently firing — 18
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.19%Above 5Y avg (0.68%)
Annual Rate
KRW 1000.00Paid annual
Payout Ratio
47.7%Sustainable
Payback Period
30.6 yr
Last Ex-Dividend
Dec 29, 2025
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
2.04TKRW1.47B · vs all stocks (USD)
Trailing P/E
15.52xvs Medical Devices peers
Revenue (TTM)
369.11BKRW266.43M · vs all stocks (USD)
Profit Margin
37.29%vs Medical Devices peers
Beta
0.6580xvs all stocks
52-Week Change
-40.83%vs all stocks
Market Capitalization
2.04TKRW1.47B · vs all stocks (USD)
Enterprise Value
2.06TKRW1.49B · vs all stocks (USD)
Trailing P/E
15.52xvs Medical Devices peers
Forward P/E
9.84xvs Medical Devices peers
PEG Ratio
2.02xvs Medical Devices peers
Price to Sales (TTM)
5.53xvs Medical Devices peers
Price to Book (MRQ)
3.68xvs Medical Devices peers
Enterprise to Revenue
5.58xvs Medical Devices peers
Enterprise to EBITDA
11.11xvs Medical Devices peers
Gross Margin
72.52%vs Medical Devices peers
Profit Margin
37.29%vs Medical Devices peers
Operating Margin
41.64%vs Medical Devices peers
Return on Assets (TTM)
15.16%vs Medical Devices peers
Return on Equity (TTM)
25.61%vs Medical Devices peers
Revenue (TTM)
369.11BKRW266.43M · vs all stocks (USD)
Revenue per Share (TTM)
5.66KKRWUpdated Sep 20, 2026Quarterly Revenue Growth
26.70%vs Medical Devices peers
Gross Profit (TTM)
277.31BKRW200.16M · vs all stocks (USD)
EBITDA (TTM)
199.96BKRW144.33M · vs all stocks (USD)
Net Income (TTM)
137.63BKRW99.34M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
7.20%vs Medical Devices peers
Operating Cash Flow (TTM)
126.14BKRW91.05M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
23.55BKRW17.00M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.00KKRWUpdated Sep 20, 2026Trailing Annual Dividend Yield
3.19%vs all stocks
5-Year Average Dividend Yield
0.68%vs all stocks
Payout Ratio
47.66%vs Medical Devices peers
Minority Interest (Equity)
-1.30BKRWFY2025 · Dec 31, 2025Revenue
336.82BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
75.73BKRWFY2025 · Dec 31, 2025Gross Profit
261.09BKRWFY2025 · Dec 31, 2025Operating Income
170.60BKRW123.14M · vs all stocks (USD)
Pre-tax Income
168.63BKRWFY2025 · Dec 31, 2025Income Tax Expense
36.66BKRWFY2025 · Dec 31, 2025Net Income
131.97BKRWFY2025 · Dec 31, 2025EBIT
171.05BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
186.75BKRWFY2025 · Dec 31, 2025Research & Development
17.44BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
45.47BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
5.36BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.42BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
131.97BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-34.33MKRWFY2025 · Dec 31, 2025Operating Cash Flow
134.36BKRWFY2025 · Dec 31, 2025Free Cash Flow
123.89BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
37.52BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
131.97BKRWFY2025 · Dec 31, 2025Stock-based Compensation
1.23BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-2.94BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-40.53BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
44.64BKRWFY2025 · Dec 31, 2025Capital Expenditures
-10.47BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-6.38BKRWFY2025 · Dec 31, 2025Purchase of Investments
-511.15BKRWFY2025 · Dec 31, 2025Sale of Investments
426.06BKRWFY2025 · Dec 31, 2025Other Investing Activity
-7.28BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-102.84BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
10.81BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-14.92BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-18.14BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-16.83BKRWFY2025 · Dec 31, 2025Other Financing Charges
48.27MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-38.97BKRWFY2025 · Dec 31, 2025Shares Outstanding
65.22MSharesUpdated Sep 20, 2026Float Shares
21.84MSharesUpdated Sep 20, 2026% Held by Insiders
55.96%vs all stocks
% Held by Institutions
19.64%vs all stocks
Total Cash (MRQ)
136.10BKRW98.24M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.09KKRWUpdated Sep 20, 2026Total Debt (MRQ)
148.37BKRW107.09M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2673xvs Medical Devices peers
Current Ratio (MRQ)
1.60xvs Medical Devices peers
Book Value per Share (MRQ)
8.51KKRWUpdated Sep 20, 2026Total Assets
704.65BKRW508.62M · vs all stocks (USD)
Total Current Assets
295.77BKRWFY2025 · Dec 31, 2025Total Liabilities
152.98BKRWFY2025 · Dec 31, 2025Total Non-current Assets
408.88BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
72.77BKRWFY2025 · Dec 31, 2025Total Current Liabilities
80.20BKRWFY2025 · Dec 31, 2025Cash
37.52BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
37.52BKRWFY2025 · Dec 31, 2025Other Short-term Investments
170.04BKRWFY2025 · Dec 31, 2025Accounts Receivable
48.37BKRWFY2025 · Dec 31, 2025Inventory
30.10BKRWFY2025 · Dec 31, 2025Accounts Payable
4.59BKRWFY2025 · Dec 31, 2025Short-term Debt
23.97BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-280.00KRWFY2025 · Dec 31, 2025Long-term Debt
62.82BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
10.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
6.63BKRWFY2025 · Dec 31, 2025Retained Earnings
547.53BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
551.67BKRW398.20M · vs all stocks (USD)
Treasury Stock
18.41BKRWFY2025 · Dec 31, 202552-Week Low
30.15KKRWUpdated Sep 20, 202652-Week High
77.60KKRWUpdated Sep 20, 202652-Week Change
-40.83%vs all stocks
Beta
0.6580xvs all stocks
50-Day MA
38.44KKRWUpdated Sep 20, 2026200-Day MA
51.00KKRWUpdated Sep 20, 2026Avg 10-Day Volume
164.30KSharesUpdated Sep 20, 2026Avg 30-Day Volume
307.08KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
2.00KKRWUpdated Sep 20, 202618 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue And Profit Growth
Revenue and earnings have both grown steadily across six years.
Reads
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
Down-Close Streak With Profitability
A run of down weeks on a company profitable three years running and funded by equity.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 41.6%, higher than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: 0.42Industry median: 0.07Industry P95: 0.34Peers compared: 102
Profit margin is 37.3%, higher than 95% of its Medical Devices peers (median 4.1%)Significant
Profit margin: 0.37Industry median: 0.04Industry P95: 0.32Peers compared: 102
Return on equity is 25.6%, higher than 95% of its Medical Devices peers (median 2.5%)Significant
Return on equity: 0.26Industry median: 0.03Industry P95: 0.17Peers compared: 102
Return on assets is 15.2%, higher than 95% of its Medical Devices peers (median 1.7%)Significant
Return on assets: 0.15Industry median: 0.02Industry P95: 0.12Peers compared: 102
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.27Receivables vs revenue divergence: 11.56
Financial Health
Altman Z-Score 10.74: safe zoneNotable
Altman Z-Score: 10.74
High earnings qualityNotable
Earnings Quality Score: 0.58
High structural barrier to entryNotable
Barrier to Entry: 0.75
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.47B, above the global median of $1.18BNotable
Market cap (USD): 1,473,465,524.136Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Omeros Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Balance Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Bochuan Electronic Co., Ltd.
15 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit GrowthMulti-Year FCF With Growth And Margin
NVIDIA Corporation
15 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year Revenue And Profit GrowthMulti-Year FCF With Growth And Margin
Computer Age Management Services Ltd.
15 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginDown-Close Streak With ProfitabilityIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And EquityMulti-Year FCF With Growth And Margin